

Qiang Sun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1219536/publications.pdf>

Version: 2024-02-01

98
papers

2,562
citations

279798

23
h-index

223800

46
g-index

110
all docs

110
docs citations

110
times ranked

4249
citing authors

#	ARTICLE	IF	CITATIONS
1	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1688-1700.	10.7	451
2	Autism-like behaviours and germline transmission in transgenic monkeys overexpressing MeCP2. <i>Nature</i> , 2016, 530, 98-102.	27.8	260
3	New insights into insulin: The anti-inflammatory effect and its clinical relevance. <i>World Journal of Diabetes</i> , 2014, 5, 89.	3.5	166
4	Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 357-366.	10.7	125
5	Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis. <i>Oncotarget</i> , 2016, 7, 46482-46491.	1.8	92
6	Extracting comprehensive clinical information for breast cancer using deep learning methods. <i>International Journal of Medical Informatics</i> , 2019, 132, 103985.	3.3	90
7	Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1774-1784.	1.6	64
8	The value of contrast-enhanced ultrasound for sentinel lymph node identification and characterisation in pre-operative breast cancer patients: A prospective study. <i>European Radiology</i> , 2018, 28, 1654-1661.	4.5	61
9	A Prognostic Model of Triple-Negative Breast Cancer Based on miR-27b-3p and Node Status. <i>PLoS ONE</i> , 2014, 9, e100664.	2.5	56
10	Prognostic Value of PD-L1 in Breast Cancer: A Meta-Analysis. <i>Breast Journal</i> , 2017, 23, 436-443.	1.0	53
11	Diagnostic Performance of Indocyanine Green-Guided Sentinel Lymph Node Biopsy in Breast Cancer: A Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0155597.	2.5	47
12	Cancer-derived exosomal miR-7641 promotes breast cancer progression and metastasis. <i>Cell Communication and Signaling</i> , 2021, 19, 20.	6.5	46
13	Expression of ALDH1 in breast invasive ductal carcinoma: an independent predictor of early tumor relapse. <i>Cancer Cell International</i> , 2013, 13, 60.	4.1	36
14	Tumoral expression of drug and xenobiotic metabolizing enzymes in breast cancer patients of different ethnicities with implications to personalized medicine. <i>Scientific Reports</i> , 2017, 7, 4747.	3.3	35
15	The prognostic comparison among unilateral, bilateral, synchronous bilateral, and metachronous bilateral breast cancer: A meta-analysis of studies from recent decade (2008-2018). <i>Cancer Medicine</i> , 2019, 8, 2908-2918.	2.8	34
16	Current Status and Factors Influencing Surgical Options for Breast Cancer in China: A Nationwide Cross-Sectional Survey of 110 Hospitals. <i>Oncologist</i> , 2020, 25, e1473-e1480.	3.7	34
17	lncRNA AFAP1-AS1 promotes triple negative breast cancer cell proliferation and invasion via targeting miR-145 to regulate MTH1 expression. <i>Scientific Reports</i> , 2020, 10, 7662.	3.3	33
18	Clinical factors associated with circulating tumor DNA (ctDNA) in primary breast cancer. <i>Molecular Oncology</i> , 2019, 13, 1033-1046.	4.6	30

#	ARTICLE	IF	CITATIONS
19	Comparison of sentinel lymph node biopsy guided by blue dye with or without indocyanine green in early breast cancer. <i>Journal of Surgical Oncology</i> , 2018, 117, 1841-1847.	1.7	29
20	Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients. <i>Frontiers in Oncology</i> , 2021, 11, 570623.	2.8	29
21	<scp>FOXC</scp>1 is associated with estrogen receptor alpha and affects sensitivity of tamoxifen treatment in breast cancer. <i>Cancer Medicine</i> , 2017, 6, 275-287.	2.8	26
22	Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 533-542.	2.5	26
23	Ultrasound-Assisted Thoracic Paravertebral Block Reduces Intraoperative Opioid Requirement and Improves Analgesia after Breast Cancer Surgery: A Randomized, Controlled, Single-Center Trial. <i>PLoS ONE</i> , 2015, 10, e0142249.	2.5	25
24	Clinical characteristics, classification and surgical treatment of periductal mastitis. <i>Journal of Thoracic Disease</i> , 2018, 10, 2420-2427.	1.4	25
25	The influence on survival of delay in the treatment initiation of screening detected non-symptomatic breast cancer. <i>Scientific Reports</i> , 2019, 9, 10158.	3.3	25
26	Rhomboid domain-containing protein 1 promotes breast cancer progression by regulating the p-Akt and CDK2 levels. <i>Cell Communication and Signaling</i> , 2018, 16, 65.	6.5	24
27	VISTA Expression on Immune Cells Correlates With Favorable Prognosis in Patients With Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 583966.	2.8	23
28	Sensitivity, Specificity and Accuracy of Ultrasound in Diagnosis of Breast Cancer Metastasis to the Axillary Lymph Nodes in Chinese Patients. <i>Ultrasound in Medicine and Biology</i> , 2015, 41, 1835-1841.	1.5	22
29	Long noncoding RNA AFAP1-AS1 promotes tumor progression and invasion by regulating the miR-2110/Sp1 axis in triple-negative breast cancer. <i>Cell Death and Disease</i> , 2021, 12, 627.	6.3	22
30	Expression and function of MutT homolog 1 in distinct subtypes of breast cancer. <i>Oncology Letters</i> , 2017, 13, 2161-2168.	1.8	20
31	TTK is a favorable prognostic biomarker for triple-negative breast cancer survival. <i>Oncotarget</i> , 2016, 7, 81815-81829.	1.8	20
32	Diagnostic Accuracy of PIK3CA Mutation Detection by Circulating Free DNA in Breast Cancer: A Meta-Analysis of Diagnostic Test Accuracy. <i>PLoS ONE</i> , 2016, 11, e0158143.	2.5	19
33	GnRHa for Ovarian Protection and the Association between AMH and Ovarian Function during Adjuvant Chemotherapy for Breast Cancer. <i>Journal of Cancer</i> , 2019, 10, 4278-4285.	2.5	18
34	Ki-67 index, progesterone receptor expression, histologic grade and tumor size in predicting breast cancer recurrence risk: A consecutive cohort study. <i>Cancer Communications</i> , 2020, 40, 181-193.	9.2	18
35	Web-Based Medical Information Searching by Chinese Patients With Breast Cancer and its Influence on Survival: Observational Study. <i>Journal of Medical Internet Research</i> , 2020, 22, e16768.	4.3	18
36	Prognosis of subtypes of the mucinous breast carcinoma in Chinese women: a population-based study of 32-year experience (1983-2014). <i>Oncotarget</i> , 2016, 7, 38864-38875.	1.8	17

#	ARTICLE	IF	CITATIONS
37	HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis. <i>Oncotarget</i> , 2016, 7, 63571-63582.	1.8	17
38	MicroRNA-27b-3p Promotes Tumor Progression and Metastasis by Inhibiting Peroxisome Proliferator-Activated Receptor Gamma in Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1371.	2.8	17
39	Platinum-Based Neoadjuvant Chemotherapy for Breast Cancer With BRCA Mutations: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 592998.	2.8	16
40	Superb Microvascular Imaging Technology Can Improve the Diagnostic Efficiency of the BI-RADS System. <i>Frontiers in Oncology</i> , 2021, 11, 634752.	2.8	16
41	Preliminary study of contrast-enhanced ultrasound in combination with blue dye vs. indocyanine green fluorescence, in combination with blue dye for sentinel lymph node biopsy in breast cancer. <i>BMC Cancer</i> , 2019, 19, 939.	2.6	15
42	Prognostic significance of branched-chain amino acid transferase 1 and CD133 in triple-negative breast cancer. <i>BMC Cancer</i> , 2020, 20, 584.	2.6	15
43	Loco-regional therapy and the risk of breast cancer-related lymphedema: a systematic review and meta-analysis. <i>Breast Cancer</i> , 2021, 28, 1261-1272.	2.9	14
44	Mammographic casting-type calcification is an independent prognostic factor in invasive breast cancer. <i>Scientific Reports</i> , 2019, 9, 10544.	3.3	13
45	Diagnostic value of an automated breast volume scanner compared with a hand-held ultrasound: a meta-analysis. <i>Gland Surgery</i> , 2019, 8, 698-711.	1.1	13
46	Fractures due to Aromatase Inhibitor Therapy for Breast Cancer: A Real-World Analysis of FAERS Data in the Past 15 Years. <i>Oncology Research and Treatment</i> , 2020, 43, 96-102.	1.2	13
47	Evaluation of the quality and readability of online information about breast cancer in China. <i>Patient Education and Counseling</i> , 2021, 104, 858-864.	2.2	13
48	The clinical features and prognosis of patients with mucinous breast carcinoma compared with those with infiltrating ductal carcinoma: a population-based study. <i>BMC Cancer</i> , 2021, 21, 536.	2.6	12
49	Automated Breast Volume Scanning: Identifying 3-D Coronal Plane Imaging Features May Help Categorize Complex Cysts. <i>Ultrasound in Medicine and Biology</i> , 2016, 42, 689-698.	1.5	11
50	A systematic surgical approach for the treatment of idiopathic granulomatous mastitis: a case series. <i>Gland Surgery</i> , 2020, 9, 261-270.	1.1	11
51	LUX-breast 1: Randomized, phase III trial of afatinib and vinorelbine versus trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS649-TPS649.	1.6	11
52	Clinicopathological characteristics and long-term prognosis of screening detected non-palpable breast cancer by ultrasound in hospital-based Chinese population (2001-2014). <i>Oncotarget</i> , 2016, 7, 76840-76851.	1.8	11
53	Omitting radiotherapy is safe in breast cancer patients 70 years old after breast-conserving surgery without axillary lymph node operation. <i>Scientific Reports</i> , 2020, 10, 19481.	3.3	10
54	miR-452 Reverses Abnormal Glycosylation Modification of ER α and Estrogen Resistance in TNBC (Triple-Negative Breast Cancer) Through Targeting UGT1A1. <i>Frontiers in Oncology</i> , 2020, 10, 1509.	2.8	10

#	ARTICLE	IF	CITATIONS
55	Validation of CTS5 model in large-scale breast cancer population and the impact of menopausal and HER2 status on its prognostic value. <i>Scientific Reports</i> , 2020, 10, 4660.	3.3	10
56	The Diagnostic Performance of Minimally Invasive Biopsy in Predicting Breast Pathological Complete Response After Neoadjuvant Systemic Therapy in Breast Cancer: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 933.	2.8	10
57	Tall cell carcinoma of the breast with reverse polarity: case report with gene sequencing and literature review. <i>Gland Surgery</i> , 2021, 10, 837-843.	1.1	10
58	Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study. <i>Oncotarget</i> , 2016, 7, 50643-50655.	1.8	10
59	Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial. <i>BMC Cancer</i> , 2020, 20, 653.	2.6	9
60	Breast-conserving surgery without axillary lymph node surgery or radiotherapy is safe for HER2-positive and triple negative breast cancer patients over 70 years of age. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 117-126.	2.5	9
61	A new avenue for obtaining insight into the functional characteristics of long noncoding RNAs associated with estrogen receptor signaling. <i>Scientific Reports</i> , 2016, 6, 31716.	3.3	8
62	Genetic factors associated with cancer racial disparity – an integrative study across twenty-one cancer types. <i>Molecular Oncology</i> , 2020, 14, 2775-2786.	4.6	8
63	Breast-conserving therapy is safe both within BRCA1/2 mutation carriers and noncarriers with breast cancer in the Chinese population. <i>Gland Surgery</i> , 2020, 9, 775-787.	1.1	8
64	Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis. <i>Breast Cancer</i> , 2021, 28, 630-643.	2.9	8
65	Breast-conserving therapy for breast cancer with BRCA mutations: a meta-analysis. <i>Breast Cancer</i> , 2022, 29, 314-323.	2.9	8
66	Genomic Profiling Comparison of Germline BRCA and Non-BRCA Carriers Reveals CCNE1 Amplification as a Risk Factor for Non-BRCA Carriers in Patients With Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 583314.	2.8	7
67	Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases. <i>Pathology and Oncology Research</i> , 2021, 27, 599894.	1.9	7
68	Novel Paradigm for Treating Idiopathic Granulomatous Mastitis. <i>Journal of Investigative Surgery</i> , 2021, 34, 816-817.	1.3	6
69	T1a triple negative breast cancer has the worst prognosis among all the small tumor (<1 cm) of TNBC and HER2-rich subtypes. <i>Gland Surgery</i> , 2021, 10, 943-952.	1.1	6
70	Serial circulating tumor DNA identification associated with the efficacy and prognosis of neoadjuvant chemotherapy in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 661-673.	2.5	6
71	Combination of preoperative fibrinogen concentration and neutrophil-to-lymphocyte ratio for prediction of the prognosis of patients with resectable breast cancer. <i>Oncology Letters</i> , 2020, 20, 1-1.	1.8	6
72	CCL2/ACKR2 interaction participate in breast cancer metastasis especially in patients with altered lipid metabolism. <i>Medical Hypotheses</i> , 2022, 158, 110734.	1.5	6

#	ARTICLE	IF	CITATIONS
73	Identification of Potential Key Genes Associated With the Pathogenesis, Metastasis, and Prognosis of Triple-Negative Breast Cancer on the Basis of Integrated Bioinformatics Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 856.	2.8	5
74	Efficacy and Safety of Anti-HER2 Agents in Combination With Chemotherapy for Metastatic HER2-Positive Breast Cancer Patient: A Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 731210.	2.8	5
75	Phosphatidylinositol-3,4,5-Trisphosphate Dependent Rac Exchange Factor 1 (PREX1) is a Novel Predictor of Prognosis for Breast Cancer Patients: A Retrospective Case Series. <i>Medical Science Monitor</i> , 2019, 25, 6554-6562.	1.1	5
76	Identification and characterization of three Siglec15-related immune and prognostic subtypes of breast-invasive cancer. <i>International Immunopharmacology</i> , 2022, 106, 108561.	3.8	5
77	Association Between Vascular Index Measured via Superb Microvascular Imaging and Molecular Subtype of Breast Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 861151.	2.8	5
78	The impact of pre-existed and SERM-induced non-alcoholic fatty liver disease on breast cancer survival: a meta-analysis. <i>Journal of Cancer</i> , 2020, 11, 4597-4604.	2.5	4
79	Clinical and sonographic features of nipple lesions. <i>Medicine (United States)</i> , 2020, 99, e19728.	1.0	4
80	Tumor biology, clinicopathological characteristics and prognosis of screen detected T1 invasive non-palpable breast cancer in asymptomatic Chinese women (2001-2014). <i>Oncotarget</i> , 2017, 8, 26221-26230.	1.8	4
81	Concurrent administration of trastuzumab and anthracyclines as adjuvant regimen for HER2-positive breast cancer: a randomised controlled trial. <i>Oncotarget</i> , 2017, 8, 92778-92787.	1.8	3
82	Comparison of CTS5 risk model and 21-gene recurrence score assay in large-scale breast cancer population and combination of CTS5 and recurrence score to develop a novel nomogram for prognosis prediction. <i>Breast</i> , 2022, 63, 61-70.	2.2	3
83	Duct ectasia in an accessory breast successfully treated with a flap technique: a case report. <i>Journal of Thoracic Disease</i> , 2016, 8, E1585-E1588.	1.4	2
84	Would 1.0 cm be a more suitable cutoff to subdivide pT1 tumors in hormone receptor-negative and HER2-positive breast cancer?. <i>Cancer Medicine</i> , 2018, 7, 5420-5430.	2.8	2
85	Mammography-detected ultrasound-negative asymptomatic micro-calcifications in Chinese women: Would it be safe to watch and wait?. <i>Medical Hypotheses</i> , 2018, 118, 9-12.	1.5	2
86	Next generation sequencing reveals CCNE1 amplification as an independent prognostic factor for triple negative breast cancer (TNBC) patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, 558-558.	1.6	2
87	Reconsidering the therapeutic use for vacuum-assisted breast biopsy in breast cancer patients: a retrospective single-center study. <i>Translational Cancer Research</i> , 2020, 9, 3879-3888.	1.0	2
88	Outcomes of re-treatment with first-line trastuzumab plus taxane in patients (pts) with metastatic breast cancer (mBC) who relapsed after (neo)adjuvant trastuzumab: A prospective multicenter study.. <i>Journal of Clinical Oncology</i> , 2016, 34, e12068-e12068.	1.6	1
89	Association of striking life events with primary breast cancer in 265 Chinese women: a case-control study. <i>Oncotarget</i> , 2017, 8, 82103-82113.	1.8	1
90	Clinical Values of Combined Diffused Optical Tomography and PET-CT in the Diagnosis of Breast Cancer. <i>Zhongguo Yi Xue Ke Xue Yuan Xue Bao Acta Academiae Medicinae Sinicae</i> , 2017, 39, 682-687.	0.2	1

#	ARTICLE	IF	CITATIONS
91	Identification and validation of an epigenetically regulated long noncoding RNA model for breast cancer metabolism and prognosis. <i>BMC Medical Genomics</i> , 2022, 15, 105.	1.5	1
92	A rare mixed breast cancer of intraductal and solid papillary with tubular carcinoma histotypes in a young woman. <i>Journal of Thoracic Disease</i> , 2017, 9, E792-E796.	1.4	0
93	Efficacy and safety of taxane plus anthracycline with or without cyclophosphamide in Chinese node-positive breast cancer patients: an open-label, randomized controlled trial. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 659-666.	2.5	0
94	Sentinel lymph node biopsy should be considered for clinically node-negative breast cancer regardless of BRCA1/2 mutation status. <i>Annals of Translational Medicine</i> , 2020, 8, 1183-1183.	1.7	0
95	Clinical and phylogenetic factors affecting the detection of genomic variants in circulating cell-free DNA for patient with primary breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, e12600-e12600.	1.6	0
96	Abstract OT1-12-03: Phase II study of pyrotinib plus nanoparticle albumin-bound (nab)-paclitaxel as adjuvant therapy for lymph node-negative (N0) or micrometastatic (N1mi), HER2-positive early breast cancer (PHAEDRA). <i>Cancer Research</i> , 2022, 82, OT1-12-03-OT1-12-03.	0.9	0
97	Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2+ early breast cancer (PHAEDRA). <i>BMC Cancer</i> , 2022, 22, 269.	2.6	0
98	Clinical Diagnosis and Treatment of Male Breast Cancer:Analysis of 24 Cases. <i>Zhongguo Yi Xue Ke Xue Yuan Xue Bao Acta Academiae Medicinae Sinicae</i> , 2017, 39, 568-572.	0.2	0